Last update Jan. 26, 2021

Etilefrine Hydrochloride

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Adrenergic sympathomimetic agent used in the treatment of orthostatic hypotension and cardiovascular syncope.
Oral or intravenous administration.

Since the last update we have not found any published data on its excretion in breast milk.

Its short half-life make transfer into breastmilk in significant quantities unlikely.
Its low oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk except in premature babies and in the immediate neonatal period during which there may be greater intestinal permeability.

Trendelemburg position, may produce the same clinical improvement as (empiric) ethylephrine or propranolol therapy (Di Girolamo 1998).

There are very few bibiographical references and it is marketed in few countries.


We do not have alternatives for Etilefrine Hydrochloride.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Etilefrine Hydrochloride is also known as

Etilefrine Hydrochloride in other languages or writings:


Etilefrine Hydrochloride belongs to this group or family:


Main tradenames from several countries containing Etilefrine Hydrochloride in its composition:


Variable Value Unit
Oral Bioavail. 12 %
Molecular weight 218 daltons
Protein Binding 23 %
pKa 9.1 -
Tmax 0.33 hours
2 hours


  1. Sanofi. Etilefrina. Ficha técnica. 2020 Full text (in our servers)
  2. Sanofi. Etilefrine. Drug Summary. 2005 Full text (in our servers)
  3. Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barsotti A. [Evaluation of the effects of diverse therapeutic treatments versus no treatment of patients with neurocardiogenic syncope]. Cardiologia. 1998 Aug;43(8):833-7. Italian. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM